Home › ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...
 

Keywords :   


ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...

2014-06-01 18:26:53| Logistics - Topix.net

ImmunoGen, Inc. , a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced the presentation of favorable clinical findings with SAR3419 from the STARLYTE Phase II trial in diffuse large B-cell lymphoma .

Tags: data phase clinical favorable

Category:Transportation and Logistics

Latest from this category

All news
16.11Tropical Storm Sara Graphics
16.11Tropical Storm Sara Forecast Discussion Number 11
16.11Tropical Storm Sara Wind Speed Probabilities Number 11
16.11Summary for Tropical Storm Sara (AT4/AL192024)
16.11Tropical Storm Sara Public Advisory Number 11
16.11Tropical Storm Sara Forecast Advisory Number 11
16.11Atlantic Tropical Weather Outlook
16.11Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
16.11HestraFallLine3
16.11GBA
16.11 SKY PAD 3.0 XL
16.1125th
16.112022taxDVD
16.11
16.11
16.11 e
More »